Genoptix Selects Zer0 to 5ive for Acquisition Announcement

Genoptix, one of the largest hematopathology centers in the United States, chose Zer0 to 5ive to announce its acquisition by leading investors, Ampersand Capital Partners and 1315 Capital. As part of the engagement, Zer0 to 5ive  raised awareness of the acquisition through targeted  coverage in  trade, local and M&A publications.


Post a Comment

You must be logged in to post a comment.